Advances in Pulmonary Hypertension CME Section
Heiko Bugger, MD, PhD - Division of Endocrinology, Metabolism and Diabetes Program in Human Molecular Biology and Genetics, University of Utah School of Medicine
E. Dale Abel, MD, PhD - Division of Endocrinology, Metabolism and Diabetes Program in Human Molecular Biology and Genetics, University of Utah School of Medicine
Paul M. Hassoun, MD - Professor of Medicine and Director of the Pulmonary Hypertension Program,
Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, School of Medicine
Kurt Stenmark, MD - Department of Pediatrics Developmental Lung Biology Laboratory, University of Colorado at Denver and Health Sciences Center
Hunter C. Champion, MD, PhD - Pulmonary Hypertension Program and Division of Cardiology, Department of Medicine, Johns Hopkins Medical Institutions
Ivan F. McMurtry, PhD - Departments of Pharmacology and Medicine and Center for Lung Biology, University of South Alabama
Program Overview
Pulmonary arterial hypertension (PAH), an incurable disease, is characterized by medial hypertrophy, intimal fibrosis, and in situ thrombi in small muscular pulmonary arteries. PAH was considered a rapidly fatal illness with a median survival of 2.8 years in the 1980s when no evidence-based therapies were available. Since then the treatment of this disease has made tremendous advances, and the last 10 years have seen the discovery of new medications that have positively influenced the prognosis and survival of patients with PAH.
This self-study activity is based on 5 articles that review the latest information on new treatments, combinations of therapies, and data from phase 1 and 2 clinical trials.
This activity is jointly sponsored by the University of Michigan Medical School and the Pulmonary Hypertension Association and supported by an unrestricted education grant from Actelion Pharmaceuticals US, Inc, Encysive Pharmaceuticals, Inc, Gilead Sciences, Inc, Pfizer, Inc, and United Therapeutics Corporation.
Target Audience
This self-study activity is appropriate for cardiologists, pulmonologists, rheumatologists, and other physicians who treat patients with pulmonary hypertension.
Learning Objectives
Upon completion of this activity participants will be able to:
- Review the various animal models used in PH research to date
- Compare and contrast the different pathological findings in animal models of PH
- Define the metabolic syndrome
- Define "diabetic cardiomyopathy"
- Review the effects of metabolic syndrome on energy production in cardiac myocytes
- Identify novel hemodynamic measurements that can be made during right heart catheterization
Self-Assessment Examination
See pages 351 and 352 for self-assessment questions, answer key, and evaluation form.
Faculty
Karen Fagan, MD
Chief, Division of Pulmonary and Critical Care Medicine
University of South Alabama
Mobile, Alabama
Contributing Authors
Heiko Bugger, MD, PhD
Division of Endocrinology, Metabolism and Diabetes
Program in Human Molecular Biology and Genetics
University of Utah School of Medicine
E. Dale Abel, MD, PhD
Division of Endocrinology, Metabolism and Diabetes
Program in Human Molecular Biology and Genetics
University of Utah School of Medicine
Paul M. Hassoun, MD
Professor of Medicine and Director of the Pulmonary Hypertension Program
Division of Pulmonary and Critical Care Medicine
Johns Hopkins University, School of Medicine
Kurt Stenmark, MD
Department of Pediatrics
Developmental Lung Biology Laboratory
University of Colorado at Denver and Health Sciences Center
Hunter C. Champion, MD, PhD
Pulmonary Hypertension Program and Division of Cardiology
Department of Medicine
Johns Hopkins Medical Institutions
Ivan F. McMurtry, PhD
Departments of Pharmacology and Medicine and Center for Lung Biology
University of South Alabama
Agenda
The Metabolic Syndrome and Cardiac Function
Heiko Bugger, MD, PhD and E. Dale Abel, MD, PhD
National Heart Lung and Blood Institute Hopkins
Specialized Center in Clinical Oriented Research
SCCOR): Molecular Determinants of Pulmonary Arterial Hypertension
Paul M. Hassoun, MD
Specialized Center in Clinical Oriented Research
(SCCOR) Update: Mechanisms and Treatment of Long Vascular Disease in Infants and Children
Kurt Stenmark, MD
Getting More From Right Heart Catheterization:
Focus on the Right Ventricle
Hunter C. Champion, MD, PhD
Animal Models of Human Severe PAH
Ivan F. McMurtry, PhD
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Michigan Medical School and the Pulmonary Hypertension Association. The University of Michigan is accredited by the ACCME to provide continuing medical education to physicians.
Credit Designation
The University of Michigan Medical School designates this activity for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim credit commensurate with the extent of their participation in the activity.
Instructions for Earning Credit
This activity is a self-study program; a self-assessment examination is included on page 351 to help physicians review important points. A form is also included on page 352 for physicians to evaluate the CME activity. Completion of this activity involves reading the journal and completing the self-assessment examination and evaluation form, which may take up to 2 hours. Credits for this self-study program are available from February 1 2009 through February 1 2010. There is no fee for this program.
Please note that this self-study program may also be viewed online at: http://www.cme.med.umich.edu
University of Michigan Privacy Statement
http://www.cme.med.umich.edu/privacy.asp
Sponsorship
This CME self-study program is jointly sponsored by the University of Michigan Medical School and the Pulmonary Hypertension Association.
Support
This CME self-study program is supported by an educational grant from Actelion Pharmaceuticals US, Inc., Encysive Pharmaceuticals, Inc., Gilead Sciences, Inc., Pfizer, Inc., and United Therapeutics Corporation.
Oversite and Accreditation
Arlene Bradford, BA
Assistant Director
Office of CME
University of Michigan Medical School
Disclosures
The Accreditation Council for Continuing Medical Education and the Association of American Colleges has standards and guidelines to ensure that individuals participating in CME activities are aware of relationships between authors and commercial companies that could potentially affect the information presented. To be disclosed to participants are all personal financial relationships with a commercial interest whose products are relevant to the content of this CME activity. The University of Michigan Medical School follows these national policies to ensure balance, independence, objectivity, and scientific rigor in all its CME activities. Each author was asked to complete a disclosure information form for this activity. Disclosures are reported below.
Karen Fagan, MD, in the past 12 months has had no relevant personal financial relationship with regard to the content of this CME activity. Dr. Fagan is on the Speaker Panel, Advisory Board and Research Review Committee of Gilead.
Heiko Bugger, MD, PhD, in the past 12 months has had no relevant personal financial relationship with regard to the content of this CME activity.
E. Dale Abel, MD, PhD, in the past 12 months has had no relevant personal financial relationship with regard to the content of this CME activity.
Paul M. Hassoun, in the past 12 months has had no relevant personal financial relationship with regard to the content of this CME activity.
Kurt Stenmark, MD, in the past 12 months has had no relevant personal financial relationship with regard to the content of this CME activity.
Hunter C. Champion, MD,PhD, in the past 12 months has had no relevant personal financial relationship with regard to the content of this CME activity. He has served as a Consultant for Actelion, Gilead, Pfizer, and United Therapeutics.
Ivan F. McMurtry, PhD, in the past 12 months has had no relevant personal financial relationship with regard to the content of this CME activity.
Arlene Bradford, BA, has no relevant personal financial relationships to disclose.
CME Reviewer
Kevin M. Chan, MD
Assistant Professor of Medicine
Division of Pulmonary and Critical Care Medicine
University of Michigan Health Systems
Ann Arbor, Michigan
Dr Chan has no relevant personal financial relationships to disclose.